Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The influence of the CYP2D6 polymorphism on psychopathological and extrapyramidal symptoms in the patients on long-term antipsychotic treatment.

Journal of psychopharmacology (Oxford, England) - 1 Nov 2006

Plesnicar Blanka Kores, Zalar Bojan, Breskvar Katja, Dolzan Vita

Abstract excerpt

Poor response to antipsychotics treatment and extrapyramidal side effects (EPS) are the most challenging problems in the treatment of schizophrenia. Several studies were investigating the impact of polymorphic cytochrome P450 2D6 gene (CYP2D6) on EPS but the results were conflicting. There are practically no clinical studies of long-term treatment of schizophrenia and CYP2D6 polymorphism. Our aim was to evaluate...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antipsychotic Agents
Share to Cytochrome P-450 CYP2D6

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Dyskinesia, Drug-Induced

Share to Long-Term Care

Share to Outpatients

Share to Psychiatric Status Rating Scales

Share to Psychotic Disorders

Share to Schizophrenic Psychology

Source

Identifiers

PMID: 16478753
DOI: 10.1177/0269881106062894

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The influence of the CYP2D6 polymorphism on psychopathological and extrapyramidal symptoms in the patients on long-term antipsychotic treatment.PMID 16478753Read ↗

CYP 2D6 polymorphism and antipsychotic therapy.Semantic proximity Read ↗

Cyp2d6*3, *4, *5 and *6 polymorphisms and antipsychotic-induced extrapyramidal side-effects in patients receiving antipsychotic therapy.Semantic proximity Read ↗

The ANKK1/DRD2 gene TaqIA polymorphism (rs1800497) is associated with the severity of extrapyramidal side effects of haloperidol treatment in CYP2D6 extensive metabolizers with schizophrenia spectrum disorders.Semantic proximity Read ↗

Non-functional CYP2D6 alleles and risk for neuroleptic-induced movement disorders in schizophrenic patients.Semantic proximity Read ↗

Into a Deeper Understanding of CYP2D6's Role in Risperidone Monotherapy and the Potential Side Effects in Schizophrenia Spectrum Disorders.Semantic proximity Read ↗

Polymorphisms in dopamine receptor DRD1 and DRD2 genes and psychopathological and extrapyramidal symptoms in patients on long-term antipsychotic treatment.Semantic proximity Read ↗

CYP1A2 and CYP2D6 Gene Polymorphisms in Schizophrenic Patients with Neuroleptic Drug-Induced Side Effects.Semantic proximity Read ↗

CYP2D6 polymorphism: implications for antipsychotic drug response, schizophrenia and personality traits.Semantic proximity Read ↗

Serotonin and dopamine receptor gene polymorphisms and the risk of extrapyramidal side effects in perphenazine-treated schizophrenic patients.Semantic proximity Read ↗

[Pharmacogenetic-based risk assessment of antipsychotic-induced extrapyramidal symptoms].Semantic proximity Read ↗

Antipsychotic-induced extrapyramidal syndromes and cytochrome P450 2D6 genotype: a case-control study.Semantic proximity Read ↗

CYP2D6 genotype and antipsychotic-induced extrapyramidal side effects in schizophrenic patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.